<ul><li>Amsterdam-based biotech startup Cradle has raised $73 million in Series B funding to support its AI-powered platform for protein engineering.</li><li>Cradle uses generative AI to design and engineer proteins, including enzymes, vaccines, peptides, and antibodies, in a more efficient and cost-effective manner.</li><li>The latest investment will help Cradle address challenges in therapeutics, diagnostics, food, chemicals, and agriculture industries, with companies like Novo Nordisk and Johnson & Johnson already using their platform.</li><li>Cradle's generative protein language model, trained on billions of sequences, significantly reduces the number of experimental rounds needed for protein development, leading to faster results and increased project success rates.</li></ul>

Biotech Startup Cradle Raises $73 Million to Boost Protein Engineering

Discover more